Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IPSS-M downstaging before transplantation does not improve the prognosis of patients with myelodysplastic neoplasms.

Bone marrow transplantation·2026
Same author

Author Correction: Consistent FFP2-masking as part of reducing viral respiratory infections on medical wards for allogeneic hematopoietic stem cell transplantation.

Scientific reports·2025
Same author

Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma-A Retrospective Multicenter Analysis.

European journal of haematology·2024
Same author

Consistent FFP2-masking as part of reducing viral respiratory infections on medical wards for allogeneic hematopoietic stem cell transplantation.

Scientific reports·2024
Same author

ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

[Proposal for participation in intensive care and emergency medicine studies for patients unable to give informed consent (Cologne Model)].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2023

Related Experiment Video

Updated: Jul 5, 2026

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol
09:12

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol

Published on: April 5, 2024

Recombinant adeno-associated virus vectors.

M Hallek1, A Girod, M Braun-Falco

  • 1Laboratorium for Molekulare Biologie, Genzentrum, Medizinische Klinik, Klinikum Innenstadt, Ludwig-Maximilians-Universität Munchen, Feodor-Lynen-Strasse 25, D-81377 München, Germany. hallek@lmb.uni-muenchen.de

Idrugs : the Investigational Drugs Journal
|May 10, 2008
PubMed
Summary

Recombinant adeno-associated virus (rAAV) shows promise for gene therapy, effectively treating cells with low immunogenicity and stable expression. Further research is refining rAAV for diverse inherited and acquired diseases.

More Related Videos

Transgene Expression in Cultured Cells Using Unpurified Recombinant Adeno-Associated Viral Vectors
06:41

Transgene Expression in Cultured Cells Using Unpurified Recombinant Adeno-Associated Viral Vectors

Published on: October 20, 2023

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform
05:51

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform

Published on: May 3, 2024

Related Experiment Videos

Last Updated: Jul 5, 2026

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol
09:12

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol

Published on: April 5, 2024

Transgene Expression in Cultured Cells Using Unpurified Recombinant Adeno-Associated Viral Vectors
06:41

Transgene Expression in Cultured Cells Using Unpurified Recombinant Adeno-Associated Viral Vectors

Published on: October 20, 2023

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform
05:51

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform

Published on: May 3, 2024

Area of Science:

  • * Molecular Biology
  • * Gene Therapy
  • * Virology

Background:

  • * Recombinant adeno-associated virus (rAAV) is a key vector in somatic gene therapy.
  • * rAAV vectors offer advantages including transduction of non-dividing cells, low pathogenicity, and stable transgene expression.
  • * Potential for targeted integration enhances therapeutic applications.

Purpose of the Study:

  • * To evaluate the potential of rAAV as a gene therapy vector.
  • * To highlight advancements in rAAV production for clinical use.
  • * To review current preclinical applications and future directions for rAAV therapy.

Main Methods:

  • * Review of preclinical studies utilizing rAAV for various genetic and acquired diseases.
  • * Analysis of rAAV properties, including host range and tissue tropism.
  • * Assessment of improved rAAV packaging methods for clinical-grade vector production.

Main Results:

  • * rAAV demonstrates high transduction efficiency in various human tissues, particularly epitheloid cells.
  • * Preclinical studies show promise for treating monogenic defects, HIV, and cancer.
  • * Improved rAAV production yields concentrated and purified vectors suitable for clinical trials.

Conclusions:

  • * rAAV is a highly promising vector for gene therapy due to its favorable characteristics.
  • * Ongoing research addresses safety, tropism, and integration for enhanced clinical utility.
  • * rAAV presents significant advantages for diverse clinical applications in gene therapy.